List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 11 studies with search of: CNTO328
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
Conditions: Ovarian Neoplasms;   Pancreatic Neoplasms;   Colorectal Neoplasms;   Head and Neck Neoplasms;   Lung Neoplasms
Intervention: Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
2 Active, not recruiting A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Condition: Prostatic Neoplasms
Intervention: Drug: CNTO 328
3 Active, not recruiting A Study of the Safety and Effectiveness of CNTO 328 (Anti IL-6 Monoclonal Antibody) in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: CNTO 328;   Biological: CNTO 328; dexamethasone
4 Suspended A Study of the Safety and Efficacy of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
Condition: Cancer, Prostate
Interventions: Biological: CNTO 328;   Drug: mitoxantrone
5 Active, not recruiting A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
Conditions: Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Giant Lymph Node Hyperplasia
Intervention: Drug: CNTO 328
6 Recruiting A Study of the Safety and Effectiveness of CNTO 328 When Added to Velcade-Melphalan-Prednisone in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: 328 plus VMP (Part 1, Part 2-Arm A);   Drug: VMP Alone (Part 2-Arm B)
7 Not yet recruiting A Study of the Safety and Efficacy of CNTO 328 in Combination With Best Supportive Care Compared to Best Supportive Care in Patients With Multicentric Castleman's Disease
Condition: Castleman's Disease
Interventions: Other: Placebo;   Drug: CNTO 328
8 Active, not recruiting A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: CNTO 328; bortezomib;   Biological: CNTO 328; placebo; bortezomib
9 Completed A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell
Intervention: Drug: CNTO 328
10 Completed CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer
Condition: Kidney Cancer
Intervention: Biological: anti-IL-6 chimeric monoclonal antibody
11 Active, not recruiting Anti-IL-6 Chimeric Monoclonal Antibody in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Condition: Prostate Cancer
Intervention: Biological: anti-IL-6 chimeric monoclonal antibody

Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services